myTomorrows Partners with The ALS Association to Support ALS Patients in Accessing Clinical Trials
NEW YORK, March 14, 2024. myTomorrows today announced a new partnership with the ALS Association, the U.S.-based nonprofit organization fighting ALS on every front.
myTomorrows is a global health technology company shaping the future landscape of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 15, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: Tralokinumab + TCS; Drug: Placebo + TCS Sponsors: LEO Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Combining EPI-7386 w/ Enzalutamide & Androgen Deprivation Therapy for Newly Diagnosed Prostate Cancer
Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Prostate Adenocarcinoma Interventions: Drug: EPI-7386; Drug: Enzalutamide; Drug: Androgen Deprivation Therapy (ADT) Sponsors: Pedro Barata, MD, MSc; ESSA Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
FOSTER CITY, Calif.--(BUSINESS WIRE) March 14, 2024 -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
TORONTO--(BUSINESS WIRE) March 13, 2024 --Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the“Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
13 March 2024 -- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( " PureTech " or the " Company " ), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Hyaluronic Acid and Polynucleotides for Supra-bony Defects
Conditions: Periodontal Diseases; Wound Heal; Periodontal Inflammation; Periodontal Pocket; Periodontal Attachment Loss Interventions: Combination Product: Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA); Procedure: Periodontal Access Flap (AF) Sponsors: Queen Mary University of London; Geistlich Pharma AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
Conditions: Healthy Vollunteer Interventions: Drug: Empagliflozin 10 mg tablets; Drug: JARDIANCE ® Sponsors: Pharma Nueva Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
LONDON--(BUSINESS WIRE) March 13, 2024 -- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the“Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Ionis Announces Positive Results from Phase 2 Study of ION224, an Investigational Medicine Demonstrating Clinical Efficacy in the Treatment of NASH/MASH
CARLSBAD, Calif., March 13, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in development for the treatment of metabolic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
OSAKA, Japan, and CAMBRIDGE, Massachusetts, March 13, 2024– Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 13, 2024 Category: Pharmaceuticals Source Type: clinical trials
Delta-8-THC Use Reported by 11% of 12th Graders in 2023
March 12, 2024 -- Use of the psychoactive cannabis product is higher in states without existing delta-8 regulations or cannabis legalization, NIH-funded study finds.
Approximately 11% of 12th-grade students across the United States reported... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 12, 2024 Category: Pharmaceuticals Source Type: clinical trials
NIH Opens Long COVID Trials to Evaluate Treatments for Autonomic Nervous System Dysfunction
March 12, 2024 -- Part of NIH’s RECOVER Initiative, trials will test at least three treatments for symptoms such as fast heart rate, dizziness and fatigue.
People 18 years of age and older who are interested in learning more about these... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 12, 2024 Category: Pharmaceuticals Source Type: clinical trials
Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
Conditions: Lentigo; Solar Lentigo; Post Inflammatory Hyperpigmentation Interventions: Device: CRYONOVE (EC14_4osc); Device: CRYONOVE (EC+05_1osc); Device: CRYONOVE (EC+05_2osc) Sponsors: Cryonove Pharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
